This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
October 27, 2021
Targovax ASA: Invitation to presentation of Targovax’s third quarter 2021 results, Thursday 4 November
October 26, 2021
Pulmonx to Report Third Quarter 2021 Financial Results on November 2, 2021
October 25, 2021
Lancet’s EClinicalMedicine publishes phase 2 data on C21 in COVID-19
October 22, 2021
Targovax invites to webcast presentation on Xtrainvestor
October 22, 2021
Oncopeptides withdraws Pepaxto® in US, scale down organization and focus on R&D
October 20, 2021
Fusion Pharmaceuticals Announces Presentation Of Preclinical Data Supporting Its FPI-1966 And FPI-2059 Targeted Alpha Therapies
October 20, 2021
Targovax ASA appoints Dr. Erik Digman Wiklund as new CEO
October 19, 2021
Germany is world’s first country to cover digital therapeutic for Burnout through universal reimbursement – free access for 50 million adults
October 19, 2021
Nordic Nanovector enters research collaboration with the University of Pennsylvania to generate a novel CD37-targeting CAR-T cell approach
October 12, 2021
Lakeside is the first healthcare provider in the UK to go live with the Doctrin platform – the second generation of digital healthcare systems from the Swedish healthtech company Doctrin